Brain

Regeneration Biomedical to Present Data on First Two Subjects in a Phase I Clinical Trial of Stem Cell Therapy delivered directly into the brains of Patients with Alzheimer’s Disease

Wnt-activated, autologous, expanded, adipose-derived stem cells administered directly into lateral ventricles of the brain via Ommaya reservoir implanted under the...

Acumen Pharmaceuticals Presents Patient Experience and Biomarker Data from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024

NEWTON, Mass., July 28, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel...

Cognition Therapeutics to Host Investor Webcast to Discuss Results from Proof-of-Concept Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease at 8:30am ET on Monday July 29, 2024

PURCHASE, N.Y., July 26, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage...

CHMP recommends RYBREVANT®▼ (amivantamab) in combination with chemotherapy for the treatment of adult patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC) after failure of prior therapy

Linus Health Acquires Together Senior Health to Expand its Platform to Better Serve Patients and Providers with End-to-End Workflow Capabilities

Company's virtual therapeutic programs and proprietary risk stratification algorithm support proactive detection of and intervention for cognitive decline BOSTON, July...

Halberd Corp’s (OTC: HALB) Groundbreaking Traumatic Brain Injury (TBI) Mitigation Nasal Spray Shows Promising Phase II Initial Test Results

JACKSON CENTER, Pa., July 24, 2024 (GLOBE NEWSWIRE) -- Halberd Corporation (OTC-PINK: "HALB”) has announced encouraging preliminary outcomes from its...

error: Content is protected !!